Compound (E)-2-(3,4-dihydroxystyryl)-3-hydroxy-4H-pyran-4-one downregulation of Galectin-3 ameliorates Aβ pathogenesis-induced neuroinflammation in 5 × FAD mice
Life Sciences · 2024
DOI: 10.1016/j.lfs.2024.123085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Sciences, 2024. Verfasst von Xueyan Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzh…. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease, Neuroinflammatory Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Fujian Provincial Health Commission, State Key Laboratory of Supramolecular Structure and Materials, Jilin University.
Abstract (Originalsprache)
AIMS: Alzheimer's disease (AD) is characterized by β-amyloid (Aβ) aggregation and neuroinflammation, leading to progressive synaptic loss and cognitive decline. Recent evidence suggests that Galectin-3 (Gal-3) plays a critical role in Aβ pathogenesis. However, strategies to simultaneously target Gal-3 and Aβ are currently insufficient. This study evaluates the therapeutic efficacy of (E)-2-(3,4-dihydroxystyryl)-3-hydroxy-4H-pyran-4-one (D30), in reducing Gal-3 and Aβ pathogenesis. MATERIALS AND METHODS: We applied exogenous oligomeric Aβ and used 5 × FAD mice to assess the impact of Aβ on Gal-3 deposition, microglial activation, and cognitive function. Thy1-EGFP mice were employed to observe dendritic spines. Comprehensive evaluations of D30's effects included behavioral studies, transcriptomic analysis, Western blotting, and immunofluorescent staining. The interaction between D30 and Gal-3 was examined using fluorescence resonance energy transfer (FRET) and microscale thermophoresis (MST). KEY FINDINGS: D30 effectively reduced Aβ monomer production by inhibiting Amyloid Precursor Protein (APP) and presenilin 1 (PS1) expression, and decreased Aβ aggregation. Treatment with D30 improved cognitive functions, reversed dendritic spine loss, and increased PSD95 expression in 5 × FAD mice. Additionally, D30 significantly lowered Gal-3 levels in both plasma and hippocampal tissues. D30 binds to Gal-3 and disrupts the interaction between Gal-3 and TREM2, as confirmed by FRET and MST. SIGNIFICANCE: Our findings underscore the interaction between Gal-3 and Aβ in AD and its role in systemic inflammation using the 5 × FAD mouse model. Being able to target and regulate Gal-3 together with Aβ is crucial for preventing neuroinflammation and protecting synapses, D30 emerged as a novel compound with promising potential for AD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350112, Fujian Province, China; School of Pharmacy, Fujian Medical…
- Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350112, Fujian Province, China; Department of Anesthesiology, Anest…
- Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350112, Fujian Province, China.
- School of Pharmacy, Fujian Medical University, Fuzhou 350112, Fujian Province, China.
- School of Pharmacy, Fujian Medical University, Fuzhou 350112, Fujian Province, China; Ningde Rehabilitation Hospital, Ningde 352105, Fujian Province, China.
- Department of Hyperbaric Oxygen, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, Fujian Province, China.
Förderung
- Fujian Provincial Health Commission
- State Key Laboratory of Supramolecular Structure and Materials
- Jilin University
- Fujian Medical University
- Natural Science Foundation of Fujian Province
Zitieren
APA
Liu, X., Chen, P., Wu, W., Zhong, M., Dong, S., Lin, H., Dai, C., Zhang, Z., Lin, S., Che, C., Xu, J., Li, C., Li, H., Pan, X., Chen, Z., Chen, X., & Ye, Z. C. (2024). Compound (E)-2-(3,4-dihydroxystyryl)-3-hydroxy-4H-pyran-4-one downregulation of Galectin-3 ameliorates Aβ pathogenesis-induced neuroinflammation in 5 × FAD mice. Life Sciences. https://doi.org/10.1016/j.lfs.2024.123085
Vancouver
Liu X, Chen P, Wu W, Zhong M, Dong S, Lin H, et al. Compound (E)-2-(3,4-dihydroxystyryl)-3-hydroxy-4H-pyran-4-one downregulation of Galectin-3 ameliorates Aβ pathogenesis-induced neuroinflammation in 5 × FAD mice. Life Sciences. 2024. doi:10.1016/j.lfs.2024.123085
BibTeX
@article{Liu2024,
author = {Liu, Xueyan and Chen, Ping and Wu, Wei and Zhong, Meihua and Dong, Shiyu and Lin, Huiling and Dai, Chaoxian and Zhang, Zhile and Lin, Shiqi and Che, Cuilan and Xu, Jiexin and Li, Chenlu and Li, Hongwei and Pan, Xiaodong and Chen, Zhou and Chen, Xiaochun and Ye, Zu-Cheng},
title = {Compound (E)-2-(3,4-dihydroxystyryl)-3-hydroxy-4H-pyran-4-one downregulation of Galectin-3 ameliorates Aβ pathogenesis-induced neuroinflammation in 5 × FAD mice},
journal = {Life Sciences},
year = {2024},
doi = {10.1016/j.lfs.2024.123085}
}
EUVIMED